Related Blog Posts from the Wikinvest Wire

Savient Pharmaceuticals (SVNT)   Subscribe to Savient Pharmaceuticals (SVNT) content from the Wikinvest Wire
 » Back to Savient Pharmac… (NASDAQ:SVNT) Stock Page

  

11/1/10Savient Pharmaceuticals Spikes On Takeover Speculation (SVNT) (Benzinga)

Shares Savient Pharmaceuticals Inc (NASDAQ: SVNT) are spiking this morning on renewed takeover speculation. The stock opened up slightly trading fairly flat until volume came in around the 12.55 level pushing the stock up to 12.81 on average volume. Option traders focused on the November OTM 20 calls, with nearly 1500 trading. The November 20 calls have an open interest of 20k contracts it is possible these trades are just closing of prior positions. Day's Range: 12.46 - 12.82 52wk...

10/28/10Benzinga's Top Upgrades (TOMO, LM, SVNT, STM) (Benzinga)

TomoTherapy Incorporated (NASDAQ: TOMO) was upgraded by William Blair from “market perform" to “outperform." TOMO's shares closed at $3.90 yesterday. Shares of TomoTherapy have moved up 1.83% this year. Macquarie upgraded Legg Mason Inc (NYSE: LM) from “neutral” to “outperform” LM's shares closed at $30.58 yesterday. Shares of Legg Mason have moved up 1.76% so far this year. Cowen & Co upgraded Savient Pharmaceuticals Inc (NASDAQ: SVNT) from "neutral" to "outperform." SVNT's...

10/27/10Benzinga's Top Downgrades (TLAB, SVNT, RCI, SDRL) (Benzinga)

Tellabs Inc (NASDAQ: TLAB) was downgraded by JP Morgan from "overweight" to "neutral." TLAB's shares closed at $7.00 yesterday. Tellabs' 52-week trading range is $5.32-$9.40. JMP Securities downgraded Savient Pharmaceuticals Inc (NASDAQ: SVNT) from "outperform" to "market perform." SVNT's stock closed at $11.51 yesterday. Savient Pharmaceuticals' 52-week trading range is $10.43-$23.46. UBS downgraded Rogers Communications Inc (NASDAQ: RCI) from "buy" to "neutral.” RCI's shares closed at...

10/26/10Benzinga's Top Pre-Market NASDAQ Gainers (MIPS, NTRS, JASO, SVNT) (Benzinga)

MIPS Technologies Inc (NASDAQ: MIPS) rose 12.58% to $11.99 in the pre-market session. MIPS reported upbeat Q1 profit. Northern Trust Corporation (NASDAQ: NTRS) added 6.18% to $50.99 in the pre-market session. According to the UK's Daily Mail, HSBC Holdings Plc is likely to make an offer of $65 per share for NTRS. JA Solar Holdings Co Ltd (NASDAQ: JASO) moved up 4.73% to $8.85 in the pre-market session. JASO has lifted its Q3 shipment projections. Savient Pharmaceuticals Inc (NASDAQ:...

10/25/10Savient Pharmaceuticals Provides Update on Strategic Alternatives (Benzinga)

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its previously announced process to identify, following the approval of KRYSTEXXA™ by the U.S. Food and Drug Administration, a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value. The Company is working toward the commercial launch of KRYSTEXXA, which it...

9/30/10Savient Pharmaceuticals Announces Dismissal of Lawsuit (Benzinga)

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the United States District Court for the Southern District of New York has dismissed the Class Action originally filed on November 25, 2008, and captioned Richard Sagall vs. Savient Pharmaceuticals, Inc., et al., against the Company and two of its former officers. The suit alleged that the Company made false and misleading statements relating to the GOUT1 and GOUT2 phase 3 clinical trials and that the Company failed to...

9/30/10Savient Pharmaceuticals: FDA Issues Resolved, Inventories Adequate, Manufacturing Clean (Benzinga)

Oppenheimer has published a research report for Savient Pharmaceuticals (NASDAQ: SVNT) and is confident in the potential M&A prospects being made available to the company. In the report, Oppenheimer writes "We note that (1) Krystexxa manufacturing is clean, in our view, boding well for discussions with potential acquirors. (2) Prior issues raised by the FDA based on its June 2009 inspection appear to be benign and have already been resolved. (3) Current inventory levels should be...

9/22/10Savient Pharmaceuticals Rising On Takeover Rumor (SVNT) (Benzinga)

Shares of Savient Pharmaceuticals Inc (NASDAQ: SVNT) just popped on rumors it could be the subject of a takeover rumor. At this time, it is not known who the potential acquirer could be, but a Reuters article posted yesterday indicated that Abbott (NYSE: ABT), Pfizer (NYSE: PFE) or Amgen (NASDAQ: AMGN) could be potential suitors. Shares of SVNT are up 58 cents to $20.86, a gain of 2.86%. Savient is a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic...

9/21/10Benzinga's Top Downgrades (OI, SVNT, X, SAFM) (Benzinga)

Owens-Illinois Inc (NYSE: OI) was downgraded by Macquarie from “outperform” to "neutral." OI's shares lost 6.12%% to $27.59 at 11.26 am. OI's earnings are likely to fall by 36.15% in this year. Leerink downgraded Savient Pharmaceuticals Inc (NASDAQ: SVNT) from "outperform" to "market perform." SVNT's shares dipped 2.07% to $20.36 at 11:30 am. SVNT's sales have fallen by 45.64% in the past five years. United States Steel Corporation (NYSE: X) was downgraded by Longbow from "buy" to...

9/16/10Oppenheimer Downgrades Savient Pharmaceuticals (Benzinga)

Oppenheimer is downgrading shares of Savient Pharmaceuticals (NASDAQ: SVNT) to Perform from Outperform. The downgrade is based exclusively on valuation after SVNT's 35% one-day price increase which pushed the shares past the former price target of $17. Oppenheimer also believes additional upside may be possible on an acquisition offer though it is cautious due to potential volatility in shares surrounding the timing and amount of the potential acquisition offer. While Savient appears...

9/16/10Benzinga's Top Pre-Market NASDAQ Losers (NPSP, ERIC, VOD, SVNT) (Benzinga)

NPS Pharmaceuticals Inc (NASDAQ: NPSP) dipped 6.51% to $6.18 in the pre-market session. NPSP has proposed a public offering of about $41.29 million of its common stock. LM Ericsson Telephone Co (NASDAQ: ERIC) lost 1.99% to $10.86 in the pre-market session. Analysts at Barclays Capital upgraded ERIC from “underweight” to “equal weight.” Vodafone Group Plc (NASDAQ: VOD) fell 1.70% to $24.85 in the pre-market session. According to the Telegraph, VOD is likely to purchase Phones4U, a...

9/15/10My day trade Alert hits a home Run today SVNT (Penny Stock DD)

[wikichart align="right" ticker="SVNT" showannotations="true" livequote="true" startdate="15-03-2010" enddate="15-09-2010" width="300" height="245"] Shares of Savient Pharmaceuticals Inc. (SVNT) are higher on the session by 29%, currently trading at $19.03. The biotechnology company based in East Brunswick, New Jersey, announced that the FDA had approved its gout treatment Krystexxa, a drug that treats a type of [...]

9/15/10Benzinga's Volume Movers (SVNT, TWGP, YHOO, VOLC) (Benzinga)

Savient Pharmaceuticals Inc (NASDAQ: SVNT) shares moved up 28.66% to $18.99 at 12:43 pm. The volume of SVNT shares traded was 3100% higher than normal. Savient's drug, Krystexxa, for gout treatment, got approval from the US Food and Drug Administration. Tower Group Inc (NASDAQ: TWGP) shares rose 5.66% to $22.78. The volume of TWGP shares traded was 2706% higher than normal. TWGP has announced the pricing of $135 million private offering of 5% Convertible Senior Notes due 2014. Yahoo! Inc...

9/15/10NASDAQ Stocks Hitting 52-Week Highs (RVBD, SVNT, HOOK, ACGL) (Benzinga)

Riverbed Technology Inc (NASDAQ: RVBD) shares jumped 3.47% to create a new 52-week high of $44.78. RVBD's quarterly revenue surged 38.70% y/y. Savient Pharmaceuticals Inc (NASDAQ: SVNT) shares gained 27.24% to touch a new 52-week high of $18.78. The Food and Drug Administration (FDA) has approved SVNT's gout drug for adults who were not getting any results from the conventional therapy. Craft Brewers Alliance Inc (NASDAQ: HOOK) shares reached $9.48 to create a new 52-week high, before...

9/15/10Savient Surges On FDA Approval (Benzinga)

Jefferies recently reported that contrary to it's expectation, the FDA approved Savient's (NASDAQ: SVNT) KRYSTEXXA on time, but with a black box warning. Jefferies continues to see limited commercial potential and supply issues for the drug. The current valuation already reflects a take-out premium so the risk/reward is viewed as unattractive. SVNT expects drug availability later this year and believes it's well advanced in its preparation for the U.S launch of KRYSTEXXA. Risks seen to...

9/15/10Mid-Day Market Movers (SVNT, CO, AUMN, G) (Benzinga)

Savient Pharmaceuticals Inc (NASDAQ: SVNT) jumped 23.17% to $18.18 at 10:19 am. Food and Drug Administration (FDA) has approved SVNT's gout drug for adults who were not getting any results from the conventional therapy. China Cord Blood Corporation (NYSE: CO) climbed 14.50% to $4.58. CO has entered into a framework agreement to form a new entity with the Zhejiang Provincial Blood Center. Golden Minerals Co (AMEX: AUMN) shares advanced 13.59% to $11.70. AUMN has reported additional high...

9/15/10Savient Pharmaceuticals Jumps On FDA's Approval Of Its Gout Drug (Benzinga)

Shares of Savient Pharmaceuticals Inc (NASDAQ: SVNT) surged in pre-market trading after the approval of its gout drug by the Food and Drug Administration (FDA). SVNT's shares surged 23.31% to $18.20 in pre-market trading. The FDA has approved SVNT's gout drug for adults who were not getting any results from conventional therapy. Savient Pharmaceuticals' shares have gained 2.79% over the past month and have risen 8.45% so far this year. Read more from Benzinga's Company news. The $2.5...

9/15/10Benzinga's Top Pre-Market NASDAQ Gainers (SVNT, CYPB, UTSI, NOVL) (Benzinga)

Savient Pharmaceuticals Inc (NASDAQ: SVNT) rose 27.37% to $18.80 in the pre-market session. FDA has approved SVNT's gout drug for adults who were not getting any results from the conventional therapy. Cypress Bioscience Inc (NASDAQ: CYPB) added 13.39% to $3.98 in the pre-market session. Ramius Value and Opportunity Advisors LLC initiated an offer to buy all the outstanding shares of CYPB at $4.25 per share. UTStarcom Inc (NASDAQ: UTSI) moved up 7.25% to $2.07 in the pre-market session....

9/15/10Day Trader's Alert: SVNT, GTXI, HRBR (Stock Wizard)

Shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) surged as much as 23% after it announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.   Shares of GTx, Inc. (NASDAQ: GTXI) soared as much as 4% after it announced today that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial,...

9/15/10FDA Approves Krystexxa For Savient Pharmaceuticals (Benzinga)

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) has its Overweight rating reiterated by JP Morgan following the Tuesday (9/14) evening announcement that the FDA has approved Krystexxa for the treatment of gout, JP Morgan reports, and the focus is expected to turn to the company's strategies concerning the future. The company has potential patent protection through 2026 and as of 2/1/2010 the company only employs 43 people, allotting for a very lean structure, which is attractive to investors. ...

9/15/10Oppenheimer Has $17 Target On Savient Pharmaceuticals (SVNT) (Benzinga)

Oppenheimer & Co. has a $17 price target on Savient Pharmaceuticals (NASDAQ: SVNT), after the FDA approved Krystexxa for refractory gout. It has an Outperform rating on shares. In the research note, Oppenheimer writes, "Importantly, (1) we do not expect the relatively benign REMS program to limit Krystexxa sales in any way. (2) In our view, pre-treatment and monitoring requirements listed in the Krystexxa label will not discourage physician usage. (3) Given management's decision to sell...

9/14/10Savient: FDA clears drug for chronic gout (Penny Stock DD)

[wikichart align="right" ticker="NASDAQ:SVNT" showannotations="true" livequote="true" startdate="15-03-2010" enddate="15-09-2010" width="300" height="245"] EAST BRUNSWICK, N.J. — Savient Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration has approved its drug for treating adult patients with a type of chronic gout that doesn't respond well to conventional therapy. The drug, dubbed Krystexxa, is made to treat adult [...]

9/14/10Savient Pharmaceuticals Drug, Krystexxa; Granted FDA Approval (SVNT) (Benzinga)

Savient Pharmaceuticals (NASDAQ: SVNT) gout drug, Krystexxa; which was denied last year, has been approved by the FDA this evening. SVNT's shares are up nearly 3 points or 21% in AH trading. (Reuters writes) "The U.S. Food and Drug Administration approved the use of Savient Pharmaceuticals Inc's (SVNT.O) gout drug in adults who do not respond to other treatments or cannot take alternatives for various reasons. Gout, a painful type of arthritis in which a build up of uric acid causes...

9/14/10Savient Pharmaceuticals Gout Drug, Krystexxa; Granted FDA Approval (SVNT) (Hedge Accordingly)

Strike this one up on the winners side of the FDA crap shoot board! Savient's gout drug,  Krystexxa; which was denied last year, has been approved by the FDA this evening. SVNT's shares are up nearly 3 points or 21% in AH trading.  ( Reuters writes ) The U.S. Food and Drug Administration approved the use of Savient Pharmaceuticals Inc's ( SVNT.O ) gout drug in adults who do not respond to other treatments or cannot take alternatives for various reasons.  Gout, a painful...

4/1/10(SVNT) Savient Pharmaceuticals Announces the FDA accepted Biologics License Application (Stock Blog Hub)

Recently, Savient Pharmaceuticals, Inc. (SVNT) announced that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its gout candidate, Krystexxa (pegloticase). The BLA was resubmitted by Savient on March 15, 2010. A response from the FDA should be out in the fourth quarter of 2010 (target date: Sept 14, 2010). As [...]

9/18/09(SVNT) Savient Pharmaceuticals Gout Drug Trials Suspended (Stock Blog Hub)

Savient Pharmaceuticals Inc. (SVNT), after meeting officials from the U.S. Food and Drug Administration (FDA) on Monday, announced that the agency does not expect further clinical trials to be conducted for its gout drug Krystexxa, as the company has now reverted to its original manufacturing process for producing phase III trial material for Krystexxa. The [...]

6/21/09FDA Calendar Updates: BDSI, SVNT Deadlines Approach (Bullish Bankers)

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded [...]

6/17/09Trading results 6/17/09 (Robert Weinstein Trading Blog)

Not the same as yesterday but a good day regardless It was a rather slow day though. My trading was done rather early today but I was able to make some gains. SVNT jumped up once again. Second time in three days that it gapped up. SVNT + 1096 I am also looking at STEC for a [...]

6/15/09Trading results 6/15/09 (Robert Weinstein Trading Blog)

SVNT moved higher today and I traded it. SVNT gave a nice shot up right away and a fade in it proved to be very profitable. Of course hitting near the HOD on the sale and the LOD on the cover doesn't hurt any either. SVNT + 710 TSRA feel again today and I covered the calls [...]

6/12/09Trading results 6/12/09 (Robert Weinstein Trading Blog)

Pretty slow day Traded SVNT during the open and did better than expected as it worked out about as good as a guy can ask for. I also watched SPNG which started out making another day of gains and then totally fell off the cliff. Was interesting to watch the action. The OTC market scares [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki